Wolfe Research Initiates Coverage On Mirum Pharmaceuticals with Outperform Rating, Announces Price Target of $145

Benzinga Newsdesk www.benzinga.com Positive 59.0%

Neg 0% Neu 0% Pos 59%

Wolfe Research analyst Kalpit Patel initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform rating and announces Price Target of $145.